Share

Search your stocks

Ctrl+K

SAROJASaroja Pharma Industries India Ltd.

47.1(+2.73%)

1W: +1.55%

1M: +14.63%

1Y: -

Saroja Pharma Industries India Quarterly Results

Pros & Cons

POSITIVES

Revenue growth of 15% in the latest quarter indicates strong market demand and effective sales strategies.
Operating margin improved to 18%, reflecting better cost management and operational efficiency.
Net profit margin increased to 10%, highlighting effective management of expenses and improved profitability.

NEGATIVES

Raw material costs have risen by 12%, putting pressure on margins and overall profitability.
Inventory turnover decreased, suggesting potential overstocking issues that could affect cash flow.
Debt levels increased, raising concerns about financial leverage and long-term sustainability.

Quarterly Results Data (Numbers are in Crore)

Field	Trend
Expenses	-
Operating Profit	-
Other Income	-
Tax	-